Achieve Life Sciences Inc (ACHV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Achieve Life Sciences Inc stock (ACHV) is currently trading at $2.90. Achieve Life Sciences Inc PS ratio (Price-to-Sales) is 5.09. Analyst consensus price target for ACHV is $15.38. WallStSmart rates ACHV as Sell.
- ACHV PE ratio analysis and historical PE chart
- ACHV PS ratio (Price-to-Sales) history and trend
- ACHV intrinsic value — DCF, Graham Number, EPV models
- ACHV stock price prediction 2025 2026 2027 2028 2029 2030
- ACHV fair value vs current price
- ACHV insider transactions and insider buying
- Is ACHV undervalued or overvalued?
- Achieve Life Sciences Inc financial analysis — revenue, earnings, cash flow
- ACHV Piotroski F-Score and Altman Z-Score
- ACHV analyst price target and Smart Rating
Achieve Life Sciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Achieve Life Sciences Inc (ACHV) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Achieve Life Sciences Inc (ACHV) Key Strengths (0)
Supporting Valuation Data
Achieve Life Sciences Inc (ACHV) Areas to Watch (6)
Company is destroying shareholder value
Very expensive relative to growth, significant premium
Very expensive at 6.3x book value
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 5.1x annual revenue
Moderate institutional interest at 46.88%
Supporting Valuation Data
Achieve Life Sciences Inc (ACHV) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, PEG Ratio, Price/Book. Some valuation metrics including PEG Ratio (17.68), Price/Sales (5.09), Price/Book (6.33) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -161.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -161.10% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and PEG Ratio are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ACHV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ACHV's Price-to-Sales ratio of 5.09x trades at a deep discount to its historical average of 30.26x (25th percentile). The current valuation is 97% below its historical high of 151.39x set in Feb 2012, and 638% above its historical low of 0.69x in Jul 2008.
WallStSmart Analysis Synopsis
Data-driven financial summary for Achieve Life Sciences Inc (ACHV) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Achieve Life Sciences Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.30 indicates a conservative balance sheet with 32M in cash.
Free cash flow is -11M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.83, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Achieve Life Sciences Inc.
Bottom Line
Achieve Life Sciences Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Achieve Life Sciences Inc(ACHV)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.